A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer
Clinical trial NCT01427933 · COMPLETED
Trial details
- NCT number
- NCT01427933
- Sponsor
- Eli Lilly and Company
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2011-11-01
- Primary completion
- 2013-09-01
- Enrollment
- 141
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.